News & Media: All

Nov 22, 2016

Jason Shafrin in MedCity News: "Precision Medicine Will Increase Drug Prices and That's A Good Thing"

PHE Senior Research Economist Jason Shafrin details the benefits and challenges of precision medicine in a new commentary for MedCity News.

To read the complete article, please click here.

Nov 15, 2016

Precision's Shih Addresses 'Peace of Mind' Value in Multiple Sclerosis News Today

PHE Research Economist Tiffany Shih's recent study, "Reconsidering the Economic Value of Multiple Sclerosis Therapies," as published in the American Journal of Managed Care, examines "peace of mind" value represented by novel MS therapies.

Click here to read a discussion of the study, includin ...

Nov 11, 2016

Lakdawalla and Goldman in STAT News: Pharma Needs a New Prescription

Precision Health Economics founders Darius Lakdawalla and Dana Goldman contribute a new commentary for STAT News: "Election Verdict: Pharma Needs a New Prescription."

To read the complete commentary, please click here.

Nov 4, 2016

Philipson and Lakdawalla in Forbes: Rethinking FDA Approval Framework

Tomas Philipson and Darius Lakdawalla address the FDA approval framework in their latest commentary for Forbes.

For the complete article, please click here.

Nov 4, 2016

PHE's Ward, Linthicum and Silverstein in Health Affairs: Examining Barriers to Value-Based Agreements

In a new blog on the Health Affairs website, PHE's Alison Sexton Ward, Mark Linthicum and Alison Silverstein examine the regulatory and legal uncertainties existing as barriers to value-based agreements for drugs.

To read the complete blog, please click here.

Oct 31, 2016

Shafrin Discusses Obamacare on NPR's 'Here and Now'

PHE's senior research economist Jason Shafrin discusses anticipated premium price surges and the future for Obamacare on NPR's "Here and Now."

For the complete audio interview, please click here.

Oct 28, 2016

Multiple PHE Authors Featured in Latest Edition of JMCP

We are proud to announce that multiple studies by PHE authors are featured in the latest edition of the JMCP.

Readers will find "Estimating the Value of New Technologies That Provide More Accurate Drug Adherence Information to Providers for Their Patients with Schizophrenia," by PHE authors Ja ...

Oct 26, 2016

PHE's Jason Shafrin Discusses Value-Based Drug Pricing in HealthcareDIVE

Precision Health Economics' senior research economist Jason Shafrin discusses value-based drug pricing and the benefits for payers in HealthcareDIVE.

To read the complete article, please click here.

Oct 6, 2016

Philipson in Forbes: Why the Drug Industry and Its Critics Are Both Wrong About How R&D Spending Affects Pricing

In Tomas Philipson' latest Forbes.com commentary, he explains why the drug industry and their critics are both wrong about how R&D spending affects pricing.

To read the complete editorial, please click here.

Sep 20, 2016

Tomas Philipson Addresses UN's Access to Medicines Panel in WSJ Op-Ed

In Tomas Philipson's op-ed for the Wall Street Journal, he addresses the UN's Access to Medicines panel findings, pointing out that restricting the patent system will make it harder, not easier, for the global poor to get medicines.

To read his complete commentary, please click here.

Sep 19, 2016

Precision to Have Strong Presence at ISPOR Europe, October 29th to November 2nd, 2016

At ISPOR's 19th Annual European Congress, to be held from October 29th - November 2nd, 2016 in Vienna, Austria, Precision will have a very strong presence.

Come visit the Precision team in Booths 1000/900/1001/901!

In addition, please look for examples of our expertise in the following sessio ...

Sep 15, 2016

Goldman, Nussbaum and Linthicum in Health Affairs: Innovation Needed in Pricing and Value Measurement

In their new Health Affairs blog post, Dana Goldman, Sam Nussbaum and Mark Linthicum make the case for advancing pricing and value measurement innovation via the launch of the Innovation and Value Initiative (IVI).

To read the complete blog post, please click here.

Sep 13, 2016

Philipson Participates in AEI Panel Debating Price of Specialty Drugs

On Monday, September 12th, 2016 at AEI, health policy experts representing practitioners and industry discussed the issue of high drug prices.

On the panel, Precision's Tomas Philipson cast doubt on the claim that research and development determine pricing, arguing that in reality causality run ...

Sep 6, 2016

Philipson in Forbes: EU vs. US Cancer Care- You Get What You Pay For

In Tomas Philipson's latest Opinion for Forbes.com, he examines cancer care in the EU vs. the US, pointing out some dramatic differences in determining cost-effectiveness.

To read the complete commentary, please click here.

Sep, 2016

PHE's Jason Shafrin Analyzes Value Frameworks for Pharmaceutical Commerce

Precision Health Economics' Senior Research Economist Jason Shafrin provides an in-depth analysis of value frameworks in his new article for Pharmaceutical Commerce: "Value frameworks are here: What to do about them?"

To read the complete article, please click here.

Aug 26, 2016

Precision's Goldman Addresses the EpiPen Controversy in STAT News

Precision Health Economics' Dana Goldman addresses the firestorm created by Mylan's dramatic price hikes for their EpiPen in a new commentary published in STAT News: "To Prevent Another EpiPen Controversy, the Government Should Step In."

To read the complete commentary, please click here.

Aug 22, 2016

Dana Goldman in the New York Times: Concierge Care Can Help Indigent Uninsured

In Dana Goldman's latest opinion piece for the New York Times, "Hospital Care for Those Who Can Afford It Helps Care for Those Who Can't," he examines the paradox of concierge care and how it may effect those without insurance.

To read the complete editorial, please click here.

Aug 17, 2016

Anupam Jena in The Guardian: Australia's New Drug Guidelines Put Cost-Cutting Before Patients

Precision Health Economics' Principal Scientific Advisor Anupam B. Jena discusses Australia's proposed new guidelines for the PBS (Pharmaceutical Benefit Scheme) in a new commentary for The Guardian.

To read the complete commentary, please click here.

Aug 4, 2016

Tomas Philipson in Forbes: Are You Just a Number?

In Tomas Phillipson's latest Forbes.com commentary (with Precision co-author Jason Shafrin), the development of new value framework criteria and it's impact on both patients and physicians are examined.

To read the complete commentary, please click here.

Jul 14, 2016

Philipson in Forbes: "If It Ain't Broke, Don't Fix It"

In Tomas Philipson's latest Op-Ed for Forbes.com, he addresses pharmaceutical innovation and the recent open letter by the UAEM: "If It Ain't Broke, Don't Fix It."

To read the complete commentary, please click here.

Jul 11, 2016

Precision's Chung, MacEwan and Goldman in Health Affairs: "One Size Fits All?"

Precision's Adrienne Chung, Joanna MacEwan, and Dana Goldman address formulary policy in a new Health Affairs blog: "Does A ‘One-Size-Fits-All’ Formulary Policy Make Sense?"

To read the complete commentary, please click here.

Jul 7, 2016

Precision's Darius Lakdawalla in the AP: A Model for More Rational Drug Prices

Precision's Darius Lakdawalla is featured in The AP's Big Story, discussing the need for a more rational drug pricing model.

To read the complete story, please click here.